Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Canakinumab + Docetaxel |
| Synonyms | |
| Therapy Description |
Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Canakinumab | Ilaris | ACZ-885 | Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077). | |
| Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03626545 | Phase III | Canakinumab + Docetaxel Docetaxel | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2) | Terminated | USA | POL | NLD | LBN | ITA | ISR | HUN | GRC | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 8 |